Lilly oral obesity drug could get FDA okay in early 2026: report

Eli Lilly (NYSE:LLY) CEO Dave Ricks said Monday that the company’s GLP-1 weight-loss pill orforglipron could receive FDA approval as soon as early 2026.

In an interview with Bloomberg TV, Ricks said the company is expecting data on the drug before